| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
Form 4: Sherif Riad, Director
Received 28,000 shares as a grant or award · Granted 88,000 Stock Option (Right to Buy) |
| 10 Nov 2026 |
Form 3: Sherif Riad, Director
No securities owned |
| 09 Nov 2026 |
Form 4: Saroj Namrata, Chief Business Officer
Sold 35,370 shares ($232K) |
| 09 Nov 2026 | FORM S-8 |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis |
| 05 Nov 2026 | 144 |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the “Company”), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive O... |
| 13 Oct 2026 |
Form 4: Anderman Todd, Chief Legal Officer
Sold 11,984 shares ($87.4K) |
| 08 Oct 2026 | 144 |
| 06 Oct 2026 |
Form 4: Kaiser Peter, Chief Development Officer
Sold 9,990 shares ($70.4K) |
| 06 Oct 2026 |
Form 4: Heier Jeffrey S., Chief Scientific Officer
Sold 10,869 shares ($76.6K) |
| 02 Oct 2026 | 144 |
| 02 Oct 2026 | 144 |
| 02 Sep 2026 |
Form 4: Notman Donald, Chief Operating Officer
Sold 1,099 shares ($11.3K) |
| 31 Aug 2026 | 144 |
| 26 Aug 2026 |
Form 4: Kaiser Peter, Chief Development Officer
Sold 3,035 shares ($32.7K) |
| 26 Aug 2026 |
Form 4: Nayak Sanjay, Chief Strategy Officer
Sold 1,897 shares ($20.4K) |
| 26 Aug 2026 |
Form 4: Heier Jeffrey S., Chief Scientific Officer
Sold 3,296 shares ($35.5K) |
Loading...